Research programme: anti-cancer therapeutics - Daiichi Sankyo Company/Max Planck Innovation/The Lead Discovery Center

Drug Profile

Research programme: anti-cancer therapeutics - Daiichi Sankyo Company/Max Planck Innovation/The Lead Discovery Center

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Daiichi Sankyo Company; Max Planck Innovation; The Lead Discovery Center
  • Class Antineoplastics
  • Mechanism of Action Cell proliferation inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 11 Jul 2017 Daiichi Sankyo Company, Max Planck Innovation and the Lead Discovery Center agree to co-develop anti-cancer therapeutics
  • 11 Jul 2017 Early research in Cancer in Germany (unspecified route)
  • 11 Jul 2017 Early research in Cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top